Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Novartis Secures Ophthalmic Diversity With Final Alcon Buyout

  • News

Executive Summary

Novartis' new eye care division, created by folding together Alcon, CIBA Vision and some of the Swiss pharma's own ophthalmic therapies, will control more than 70 percent of the global eye care market at its inception. And it has a range of pipeline projects in the works to support that hegemony going forward

You may also be interested in...



The Sound Of Opportunity: Novartis Inks Deal With GenVec For Hearing Loss R&D

GenVec's gene-based program targets a hearing loss world ruled by devices.

The Sound Of Opportunity: Novartis Inks Deal With GenVec For Hearing Loss R&D

GenVec's gene-based program targets a hearing loss world ruled by devices.

Novartis Seeks Eye Care Leadership With Full, $50 Billion Alcon Takeover

Novartis pays $28.1 billion for a further 52 percent stake in Alcon, seeking full control with a further offer to buy out minority shareholders.

Table

View full table

Related Content

Scrip
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS051822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By